Using a treat-and-extend regimen in routine clinical practice for patients with neovascular age-related macular degeneration (AMD) achieves good visual outcomes and decreases treatments and clinic visits, according to a study in Ophthalmology.
Because the temperature decrease in the filtering bleb after trabeculectomy provides information about its function, a new ocular surface-oriented, infrared radiation thermographic device (TG 1000, Tomey) may help evaluate filtering bleb function. The device is easy to handle and creates reproducible measurements, according to new research published in the Journal of Glaucoma.
Ocriplasmin (Jetrea, ThromboGenics) is an option for the management of patients who have full-thickness macular hole (FTMH) and vitreomacular adhesion, according to an article in press in the American Journal of Ophthalmology.
Corneal collagen crosslinking (CXL) with epithelial disruption appears to safely and effectively treat keratoconus or iatrogenic corneal ectasia, according to a study recently published in Eye. In fact, patients may tolerate the approach better than they tolerate the technique involving complete removal of the epithelium, say the authors, from the Corneoplastic Unit and Eye Bank of Queen Victoria Hospital in East Grinstead, UK.
In SMILE the anterior-most stromal lamellae remain intact postoperatively. Here, the author discusses the biomechanical advantages of preserving the stronger anterior stroma and the resulting effects on spherical aberration control and optical quality.
Intracameral antibiotic therapy helps prevent endophthalmitis after cataract surgery, while topical antibiotic therapy does not, according to a literature review conducted by researchers from Denmark and published online in Acta Ophthalmologica.
A new trifocal diffractive IOL (FineVision trifocal IOL, PhysIOL), implanted bilaterally, achieved a full range of adequate vision, satisfactory contrast sensitivity, and a lack of significant adverse photic phenomena, according to Spanish researchers reporting in BMC Ophthalmology.
Intravitreal ranibizumab (IVR) has been found to improve vision related quality of life in diabetic macular oedema (DME) patients, notes a study recently published in the Journal of Diabetes and Its Complications.